2012
Patterns and Loss of Sexual Activity in the Year Following Hospitalization for Acute Myocardial Infarction (a United States National Multisite Observational Study)
Lindau ST, Abramsohn E, Gosch K, Wroblewski K, Spatz ES, Chan PS, Spertus J, Krumholz HM. Patterns and Loss of Sexual Activity in the Year Following Hospitalization for Acute Myocardial Infarction (a United States National Multisite Observational Study). The American Journal Of Cardiology 2012, 109: 1439-1444. PMID: 22546209, PMCID: PMC3341956, DOI: 10.1016/j.amjcard.2012.01.355.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionActivity 1 yearSexual activityMyocardial infarctionMain outcome measurementsActivity-related outcomesThird of womenMultivariable hierarchical modelsHospital discharge instructionsLack of counselingMultisite observational studyCorrelates of lossTRIUMPH registryPhysician counselingDischarge counselingYear mortalityDischarge instructionsMean ageObservational studyOutcome measurementsHospitalizationFirst monthPatientsMortalityInfarction
2009
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose